• 1
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edn. American Psychiatric Association, Washington, DC, 2013.
  • 2
    Christenson GA, Mackenzie TB, Mitchell JE. Characteristics of 60 adult chronic hair pullers. Am. J. Psychiatry 1991; 148: 365370.
  • 3
    Goodman WK. Obsessive-compulsive disorder: Diagnosis and treatment. J. Clin. Psychiatry 1999; 60: 2732.
  • 4
    DuPont RL, Rice DP, Shiraki S, Rowland CR. Economic costs of obsessive-compulsive disorder. Med. Interface 1995; 8: 102109.
  • 5
    Steketee G. Disability and family burden in obsessive-compulsive disorder. Can. J. Psychiatry 1997; 42: 919928.
  • 6
    Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr. Clin. North Am. 2000; 23: 509517.
  • 7
    Berlin HA, Koran LM, Jenike MA et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 2011; 72: 716721.
  • 8
    Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial. CNS Spectr. 2010; 15: 613617.
  • 9
    Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J. Biol. Psychiatry 2008; 9: 248312.
  • 10
    Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2005; 19: 567596.
  • 11
    Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol Biol. Psychiatry 2006; 30: 400412.
  • 12
    McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry 2000; 57: 794801.
  • 13
    Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry 1996; 57: 303306.
  • 14
    Coric V, Taskiran S, Pittenger C et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial. Biol. Psychiatry 2005; 58: 424428.
  • 15
    Faravelli C, Salvatori S, Galassi F, Aiazzi L, Drei C, Cabras P. Epidemiology of somatoform disorders: A community survey in Florence. Soc. Psychiatry Psychiatr. Epidemiol. 1997; 32: 2429.
  • 16
    Phillips KA. Body dysmorphic disorder: The distress of imagined ugliness. Am. J. Psychiatry 1991; 148: 11381149.
  • 17
    Bienvenu OJ, Samuels JF, Riddle M et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: Results from a family study. Biol. Psychiatry 2000; 48: 287293.
  • 18
    Koran LM, Abujaoude E, Large MD, Serpe RT. The prevalence of body dysmorphic disorder in the United States adult population. CNS Spectr. 2008; 13: 316322.
  • 19
    Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E. The prevalence of body dysmorphic disorder: A population-based survey. Psychol. Med. 2006; 36: 877885.
  • 20
    Phillips KA, Menard W. A prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009; 14: 252260.
  • 21
    Didie ER, Menard W, Stern AP, Phillips KA. Occupational functioning and impairment in adults with body dysmorphic disorder. Compr. Psychiatry 2008; 49: 561569.
  • 22
    Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. Body Image 2008; 5: 1327.
  • 23
    Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch. Gen. Psychiatry 2002; 59: 381388.
  • 24
    Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J. Clin. Psychiatry 1998; 59: 165171.
  • 25
    Diefenbach GJ, Tolin DF, Hanna S, Crocetto J, Worhunsky P. Trichotillomania: Impact on psychosocial functioning and quality of life. Behav. Res. Ther. 2005; 43: 869884.
  • 26
    Lochner C, Seedat S, Niehaus DJ, Stein DJ. Topiramate in the treatment of trichotillomania: An open-label pilot study. Int. Clin. Psychopharmacol. 2006; 21: 255259.
  • 27
    Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15: 351359.
  • 28
    Grant JE, Odlaug BL, Chamberlain SR, Kim SW. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: Treatment efficacy and neurocognitive predictors of response. J. Clin. Psychopharmacol. 2010; 30: 396403.
  • 29
    Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive–compulsive disorder. Int. J. Neuropsychopharmacol. 2001; 4: 179190.
  • 30
    Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 6981.
  • 31
    Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 2001; 4: 179190.
  • 32
    Moore GJ, MacMaster FP, Stewart C, Rosenberg DR. Case study: Caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry 1998; 37: 663667.
  • 33
    Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J. Am. Acad. Child Adolesc. Psychiatry 2000; 39: 10961103.
  • 34
    Rosenberg DR, Mirza Y, Russell A et al. Reduced anterior cingulated glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 11461153.
  • 35
    Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005; 30: 17351740.
  • 36
    Gitto R, De Luca L, De Grazia S, Chimirri A. Glutamatergic neurotransmission as molecular target of new anticonvulsants. Curr. Top. Med. Chem. 2012; 12: 971993.
  • 37
    Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurother. 2007; 4: 1861.
  • 38
    Lapidus KA, Soleimani L, Murrough JW. Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr. Dis. Treat. 2013; 9: 11011112.
  • 39
    Martinotti G, Lupi M, Sarchione F et al. The potential of pregabalin in neurology, psychiatry and addiction: A qualitative overview. Curr. Pharm. Des. 2013; 19: 63676374.
  • 40
    Bruno A, Mico U, Pandolfo G et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. J. Psychopharmacol. 2012; 26: 14561462.
  • 41
    Oulis P, Mourikis I, Konstantakopoulos G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 2011; 26: 221224.
  • 42
    Onder E, Tural U, Gokbakan M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur. Arch. Psychiatry Clin. Neurosci. 2008; 258: 319323.
  • 43
    Rubio G, Jimenez-Arriero MA, Martinez-Gras I, Manzanares J, Palomo T. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol. 2006; 26: 341344.
  • 44
    Grant JE, Odlaug BL, Kim SW. Lamotrigine treatment of pathologic skin picking: An open-label study. J. Clin. Psychiatry 2007; 68: 13841391.
  • 45
    Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch. Gen. Psychiatry 1989; 46: 10061011.
  • 46
    Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. National Institute for Mental Health, RockVille, MD, 1976.
  • 47
    Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 5662.
  • 48
    Spreen O, Benton AL. Neurosensory Center Comprehensive Examination For Aphasia (NCCEA). University of Victoria Neuropsychology Laboratory, Victoria, 1977.
  • 49
    Heaton RK, Chelune GI, Talley JL. Wisconsin Card Sorting Test Manual: Revised and Expanded. Psychological Assessment Resources, Odessa, FL, 1993.
  • 50
    Trenerry MR, Crosson B, Deboe J. Stroop Neuropsychological Screening Test. Psychological Assessment Resources, Odessa, FL, 1989.
  • 51
    Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol. Bull. 1997; 33: 1722.
  • 52
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychaitric Association, Washington, DC, 1994.
  • 53
    Arnold LM, Mutasim DF, Dwight MM, Lamerson CL, Morris EM, McElroy SL. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J. Clin. Psychopharmacol. 1999; 19: 1518.
  • 54
    Sheehan DV. The Anxiety Disease. Scribner's, New York, 1983.
  • 55
    Cantabeclipse. Version 3.0.0. Cambridge Cognition Limited, Cambridge, 2006.
  • 56
    Keuthen NJ, O'Sullivan RL, Ricciardi JN et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 1. Development and factor analyses. Psychother. Psychosom. 1995; 64: 141145.
  • 57
    Schruers K, Koning K, Luermans J, Haack MJ, Griez E. Obsessive-compulsive disorder: A critical review of therapeutic perspectives. Acta Psychiatr. Scand. 2005; 111: 261271.